Edition:
United States

Profile: Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

81.50CHF
11:29am EST
Change (% chg)

CHF1.35 (+1.68%)
Prev Close
CHF80.15
Open
CHF80.25
Day's High
CHF82.80
Day's Low
CHF80.00
Volume
216,639
Avg. Vol
48,336
52-wk High
CHF84.65
52-wk Low
CHF61.20

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Company Address

Basilea Pharmaceutica AG

Grenzacherstrasse 487
PO Box
BASEL     4058
P: +4161.6061111
F: +4161.6061112

Company Web Links